



FCF Fox Corporate Finance | FCF Healthcare & Life Sciences
Healthcare & Life Sciences Venture Capital Monitor – Europe


July 2023

Antibody



THE FINANCING SPECIALIST

**FCF HEALTHCARE & LIFE SCIENCES
OVERVIEW**



Overview



Focus on Biotech, MedTech and HealthTech

We advise innovative companies on arranging, structuring and placing equity, debt, and licensing transactions in a holistic financing approach



Focus Areas

FCF advises on the following transaction types:



FCF Healthcare & Life Sciences
advises leading HC & LS companies in Europe in financing transactions

Over **EUR 2bn** Healthcare & Life Sciences transaction volume
(Professionals and Advisors)

Healthcare & Life Sciences Team of **>12**

Over **100** years in aggregated Healthcare & Life Sciences experience

Access to **> 1,500** international investors

Company Valuation
in partnership with **BioScience Valuation GmbH**

China Licensing
in partnership with **YAFO Capital**

Leading EIB advisor in Europe

Over **80** completed Healthcare & Life Sciences transactions
(Professionals and Advisors)

8 regularly published Healthcare & Life Sciences reports

Healthcare & Life Sciences Team



Dr. Alexandra Goll
Advisor – Venture Capital



Dr. Axel Polack
Advisor – Science & Technology



Claus Schalper
Advisor – Corporate Affairs



Mathias Klozenbuecher
Head of Healthcare & Life Sciences



Johannes Link
Healthcare & Life Sciences Banking – Europe



Marcel Christou
Healthcare & Life Sciences Banking – Europe



Enno Spillner
Advisor – Capital Markets



Dr. Joachim M. Greuel
Advisor – Valuations



Prof. Dr. Horst Domdey
Advisor – Science & Technology



Zaid Maleh
Healthcare & Life Sciences Banking – Dubai



Sean Jian, CFA
Healthcare & Life Sciences Banking – China



Services

- ✓ Integrated Financial Modelling
- ✓ Investor Screening
- ✓ Management Presentation
- ✓ Post-Transaction Support
- ✓ Due Diligence Support
- ✓ Financing Strategy Advisory
- ✓ Investor / IR Roadshow
- ✓ Equity & Debt Fundraising
- ✓ Term Sheet Negotiation
- ✓ Life Science Advisory Board
- ✓ Closing Assistance
- ✓ IPO Execution Support

(extract from service portfolio)

Our capital markets research feeds our proprietary investor database

Data Collection

Healthcare & Life Sciences

Venture Capital Monitor – EU



- *Venture Capital*
- *Healthcare & Life Sciences*
- *Focus on Europe*

Healthcare & Life Sciences Venture Capital Report



- *Venture Capital*
- *Healthcare & Life Sciences*
- *Focus on Europe and the US*

Biotech Public Equity Monitor



- *Public Equity*
- *Biotech*
- *Focus on Europe*

Healthcare & Life Sciences IPO Report



- *IPOs*
- *Healthcare & Life Sciences*
- *Focus on Europe and the US*

Biotech Venture Capital Monitor – US



- *Venture Capital*
- *Life Sciences*
- *Focus on the US*

Biotech Licensing Monitor – China



- *Licensing*
- *Biotech*
- *Focus on Europe and Chinese licensors*

MedTech Public Equity Monitor



- *Public Equity*
- *MedTech*
- *Focus on Europe*

Healthcare & Life Sciences SPAC Monitor




- *SPACs*
- *Life Sciences*
- *Focus on US / Europe and US SPACs*

Market Monitoring

Data Processing

- *Transaction data*
- *Investment preferences*




Constant Data Enrichment

- *Ongoing investor communication*
- *Data validation*

Proprietary Investor Database

- *Most comprehensive database*
- *> 1,300,000 data points*



Data-driven Investor Selection



- *Intelligent search algorithms*
- *Big data sequencing*

Executive Summary

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is a monthly published overview focusing on the venture capital financing environment in the Biotech, Pharmaceutical, MedTech and HealthTech segments, and can be used as a quick reference for investors, corporates and professionals

More advanced, detailed and / or customized reports are available upon request

FCF Healthcare & Life Sciences Venture Capital Monitor - Europe

is a monthly published overview of Biotech, Pharmaceutical, MedTech and HealthTech companies, displaying venture capital financing trends in the European healthcare & life science industry

Scope

The selection of companies is based on the following criteria:

- Focus on transactions with European headquartered healthcare & life science companies and available deal volume
- Companies operating in the Biotech, Pharmaceutical, MedTech, HealthTech, Services or other life science related sectors
- The Biotech sector is further divided into the following therapy areas / indications: Cardiovascular, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, Nutritional Disorders, Oncology, Ophthalmology, Respiratory, Toxicology, Women's Health

To recommend colleagues or fellow investors to be added to the mailing list, kindly send an email with the respective contact information

Recipients

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe targets the following recipients:

- Corporates / Executives
- Institutional investors
- Private equity investors
- Venture capital investors
- Family Offices / High-net-worth individuals
- Advisors

Availability

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is available on FCF's website at "<https://www-fcf-de/de/life-sciences/>"

Data

All input data is provided by Pitchbook and is not independently verified by FCF- Ratio and multiple calculations are driven based on the input data available- For additional information and disclaimer, please refer to the last page

If you have questions, comments or ideas, please do not hesitate to contact us


**EUROPEAN VENTURE CAPITAL TRANSACTIONS
IN HEALTHCARE & LIFE SCIENCES**

JULY 2023




Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	142	F
3	Amolyt Pharma	France	130	C
4	Ellipses Pharma	UK	126	A
5	Hemab Therapeutics	Denmark	125	B

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	European Innovation Council Fund	Germany	147	26
2	Revival Healthcare Capital	USA	142	2
3	Gilde Healthcare Partners	Denmark	108	8
4	Forbion	Denmark	102	8
5	Jeito	France	90	6

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
1	31.07.2023	Genomika	LTU	HealthTech	Clinical Data Platform / Undisclosed	Operator of a deep tech platform intended to develop DNA storage solutions.	A	5	5	The company raised EUR 5 million of venture funding from European Innovation Council, Switzerland and the UK Fund on July 31, 2023. The funds will be used by the company to expand its laboratory premises, purchasing advanced equipment and attracting talented specialists.
2	31.07.2023	Béa Fertility	GBR	MedTech	Women's Health / Undisclosed	Developer of fertility therapy devices designed to provide clinical-standard fertility treatment at home.	A	3	4	The company raised \$3.2 million of venture funding in a deal led by Octopus Ventures on July 31, 2023. QVentures, Calm/Storm Ventures, JamJar Investments, and Forward Partners also participated in the round.
3	28.07.2023	Post-ICU	NLD	HealthTech	Clinical Management Platform / Undisclosed	Developer of a healthcare platform designed to assemble medical records after post-icu for healthcare professionals.	A	1	1	The company raised EUR 1 million of venture funding from Brabantse Ontwikkelings Maatschappij and Shaping Impact Group on July 28, 2023.
4	27.07.2023	Microplate Dx	GBR	MedTech	Diagnostic Platform / Undisclosed	Developer of a diagnostic technology designed to vastly reduce deaths from drug-resistant infections.	A	1	2	The company raised \$1.42 million of venture funding from undisclosed investors on July 27, 2023.
5	26.07.2023	Entia	GBR	MedTech	Monitoring Device / On market	Developer of healthcare monitoring devices designed to improve cancer treatment and other life-changing health conditions.	A	18	46	The company raised \$20 million of Series A funding in a deal led by BGF and Parkwalk Advisors on July 26, 2023. Other undisclosed investors also participated in the round.
6	26.07.2023	Digostics	GBR	MedTech	Diabetes Management / Undisclosed	Developer of a glucose tolerance testing platform designed to assist users to perform designed to assist users to perform test at home.	A	< 1	2	The company raised \$673,502 of angel funding from undisclosed investors on July 26, 2023.
7	24.07.2023	Crescendo Biologics	GBR	Biotech / Pharma	Oncology / Phase I	Operator of a clinical-stage immuno-oncology company intended to develop potent, multi-functional human body therapeutics in oncology.	E	29	231	The company raised \$32 million of venture funding from Kreos Capital, Sofinnova Partners, Andera Partners, IP Group BioNTech, Takeda and Quan Capital and other undisclosed investors on July 24, 2023.
8	19.07.2023	New Wave Biotech	GBR	Biotech / Pharma	Other / On Market	Developer of scale alt protein production technology designed to optimize downstream processing through virtual experimentation for protein precision fermentation.	A	< 1	< 1	The company joined Big Idea Ventures as a part of its Paris Accelerator on July 19, 2023 and received \$125,000 in funding.


Source: PitchBook as of 04-08-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	142	F
3	Amolyt Pharma	France	130	C
4	Ellipses Pharma	UK	126	A
5	Hemab Therapeutics	Denmark	125	B

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	European Innovation Council Fund	Germany	147	26
2	Revival Healthcare Capital	USA	142	2
3	Gilde Healthcare Partners	Denmark	108	8
4	Forbion	Denmark	102	8
5	Jeito	France	90	6

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
9	19.07.2023	PfX Biotech	PRT	Biotech / Pharma	Other / On Market	Producer of human milk proteins intended to commercialize bioactive and functional proteins as alternative protein ingredients for use in pediatric and advanced nutrition.	A	< 1	< 1	The company joined Big Idea Ventures as part of its New Protein accelerator program Cohort 1 on July 19, 2023 and received \$125,000 in pre-seed funding.
10	18.07.2023	Aviwell	FRA	HealthTech	AI Software / Developing	Operator of a sustainable microbiota-based Artificial Intelligence/Machine Learning (AI/ML) discovery platform intended to operate at the convergence of digital and life sciences.	A	9	9	The company raised EUR 9 million of venture funding led by Elaia Partners and MFS Impact Investment Development on July 18, 2023. The funds will be used to boost the company's breeding solutions.
11	18.07.2023	CathVision	DNK	MedTech	Electrophysiology Recording System / On Market	Developer of an electrophysiology recording technology designed to diagnose and treat cardiac arrhythmia.	-	8	37	The company raised \$9 million of venture funding from undisclosed investors on July 18, 2023. The funds will be used to support the acceleration of commercial adoption through 2024 as the company position to significantly impact, throughout the United States, and help physicians treat cardiac arrhythmias more effectively.
12	18.07.2023	MyCareforce	PRT	HealthTech	Clinical Management Platform / On market	Developer of staffing and scheduling platform designed to connect nurses and carers to available shifts.	A	1	2	The company raised BRL 6.5 million of venture funding in a deal led by Shilling (Portugal) on July 18, 2023. Demium Capital, Portugal Ventures, Humberto Ayres Pereira, and Vasco Lopes Da Silva also participated in the round.
13	18.07.2023	Healz	ESP	HealthTech	Health Monitoring Software / On market	Operator of a SaaS health and lifestyle platform intended to solve nutrition, performance, sleep, stress and fatigue problems.	A	< 1	1	The company raised EUR 500,000 of venture funding in a deal led by The Lab Ventures on July 18, 2023. Other undisclosed investors also participated in the round. The funding will be used to advance in the development of its technological platform, search for new functionalities and make the international leap.
14	14.07.2023	GenePlanet	SVN	Healthcare Services	Genetic Testing Platform / On market	Developer of genetic testing technology designed to tune the lifestyle of people.	B	20	30	The company raised EUR 20 million of Series B venture funding in a deal led by BlackPeak Capital on July 14, 2023. Kolektor Ventures, FMR, Darwin Private Equity, and Designed Impact Ventures also participated in the round. The funds will be used for supporting the further global expansion of GenePlanet, with a strategic focus on Europe and Latin America. It will also encourage the development of new products and invest significantly in building a robust big data infrastructure.
15	13.07.2023	Causaly	GBR	HealthTech	Biomedical Platform / On Market	Developer of a biomedical platform designed to find evidence, explore hidden connections, and make new predictions in biomedical science.	B	55	82	The company raised \$60 million of Series B venture funding in a deal led by ICONIQ Growth on July 13, 2023, putting the company's pre-money valuation at \$250 million. Marathon Venture Capital, Pentech Ventures, EBRD Venture Capital Investment Programme, Index Ventures, and Visionaries Club also participated in the round. The funds will be used to expand the reach of its AI-powered research platform, which is designed to save scientists from sifting through thousands of scientific publications as they identify, create and test new drugs.
16	13.07.2023	EG 427	FRA	Biotech / Pharma	Central Nervous System / Pre-clinic	Developer of a pinpoint gene therapy intended to cure spinal cord injury-related disorders.	A	18	20	The company raised EUR 18 million through the combination of debt and Series A venture funding in a deal led by David Lamond on July 13, 2023, putting the company's pre-money valuation at EUR 18.41 million. Cohesion Bureau also participated in the round. The funds will be used to advance the company's pipeline, culminating in the investigational new drug application filing in Q1 2024 for the first clinical study of its lead product.


Source: PitchBook as of 04-08-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	142	F
3	Amolyt Pharma	France	130	C
4	Ellipses Pharma	UK	126	A
5	Hemab Therapeutics	Denmark	125	B

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	European Innovation Council Fund	Germany	147	26
2	Revival Healthcare Capital	USA	142	2
3	Gilde Healthcare Partners	Denmark	108	8
4	Forbion	Denmark	102	8
5	Jeito	France	90	6

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
17	13.07.2023	Union Therapeutics	DNK	Biotech / Pharma	Infectious Diseases / On market	Operator of a clinical-stage, diversified pharmaceutical company intended to focus on identifying, developing, and commercializing treatments for immunology and infectious diseases.	C	16	87	The company raised DKK 122.6 million of venture funding through the combination of equity and convertible debt from undisclosed investors on July 13, 2023.
18	12.07.2023	Tenpoint Therapeutics	GBR	Biotech / Pharma	Ophthalmology / On Market	Operator of a biotechnology platform intended to restore vision for people with degenerative ocular diseases.	A	64	131	The company raised \$70 million of Series A venture funding led by F-Prime Capital, Sofinnova Partners and British Patient Capital on July 12, 2023. Qiming Venture Partners USA also participated in the round.
19	12.07.2023	Sencure	NLD	MedTech	Wearable Device / Developing	Developer of medical wearables designed to measure electrophysiological parameters on the human body.	C	5	9	The company raised EUR 5 million of venture funding in a deal led by Cottonwood Technology Fund on July 12, 2023. Noordelijke Ontwikkelings Maatschappij, Lumana Invest, and other undisclosed investors also participated in the round. The funds will be used to accelerate the industrialization of the company's flagship product, which is recognized for its capacity to monitor superior electrophysiological signals with 'exceptional' power efficiency.
20	12.07.2023	Oasis Diagnostics (Diagnostic Equipment)	POL	MedTech	Women's Health / Undisclosed	Developer of a vaginal diagnostic device designed to detect and properly diagnose problems with sphincter injury.	-	3	3	The company raised PLN 14 million of venture funding from Bank Gospodarstwa Krajowego and Vinci (Warsaw) on July 12, 2023.
21	12.07.2023	Better Medicine	EST	HealthTech	AI Software / Undisclosed	Developer of AI-based healthcare tools designed to diagnose and fight cancer in more efficient and accurate ways.	A	3	3	The company joined EIC Accelerator on July 12, 2023 and received EUR 2.5 million in funding in the form of grant.
22	11.07.2023	GeneCode	EST	Biotech / Pharma	Neurology / On market	Developer of disease-modifying therapeutics designed to treat neurodegeneration diseases.	A	16	14	The company graduated from European Innovation Council Fund on July 11, 2023 and received EUR 1.7 million in grant funding and EUR 14.3 million in equity investments. The funds will be used to support the development of a drug and treatment to slow the progression in Parkinson's disease.
23	11.07.2023	Sonio (Decision/Risk Analysis)	FRA	HealthTech	AI Software / Undisclosed	Developer of an artificial intelligence-based fetal ultrasound software intended to analyze and diagnose congenital malformations.	A	13	25	The company raised \$14 million of Series A venture funding in a deal led by Elaia Partners and Cross Border Impact Ventures on July 11, 2023. OneRagtime, Bpifrance, EASME - EU Executive Agency for SMEs, Dominique Gaillard, Yann Fleureau and Alain Decombe also participated in the round. The funds will be used to advance the company's SaaS solution, expanding its presence in the United States and adapting its technology for portable ultrasound scanners.
24	11.07.2023	Trainm	BEL	HealthTech	Neurological Rehabilitation / On market	Operator of neurorehabilitation center intended to help children and adults with neurological deficits achieve measurable recoveries.	D	6	10	The company raised EUR 5.5 million of venture funding from Participatiemaatschappij Vlaanderen and other undisclosed investors on July 11, 2023. The funds will be used for the development of a state-of-the-art neuro rehabilitation clinic in Amsterdam.


Source: PitchBook as of 04-08-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	142	F
3	Amolyt Pharma	France	130	C
4	Ellipses Pharma	UK	126	A
5	Hemab Therapeutics	Denmark	125	B

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	European Innovation Council Fund	Germany	147	26
2	Revival Healthcare Capital	USA	142	2
3	Gilde Healthcare Partners	Denmark	108	8
4	Forbion	Denmark	102	8
5	Jeito	France	90	6

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
25	11.07.2023	Piur Imaging	AUT	MedTech	Tomographic Ultrasound Technology / On Market	Developer of a tomographic ultrasound technology designed to make vascular imaging affordable and safe.	A	5	5	The company raised EUR 4.9 million of Series A venture funding in a deal led by Ascend Capital Partners on July 11, 2023. Aescuvest and other undisclosed investors also participated in the round. The funds will be used to rework and relaunch a major software update and a second-generation sensor and also grow its commercial team and user base, as well as scale its current focus markets that is Germany, Italy, Spain, and France, and create initial sales in the USA.
26	11.07.2023	52North	GBR	MedTech	Blood Analysis Device / Undisclosed	Operator of a low-cost finger prick blood test and digital platform designed to significantly improve safety and quality of life for cancer patients at risk of sepsis.	A	< 1	2	The company joined Cedars-Sinai as a part of its ninth cohort on July 11, 2023 and received GBP 100,000 in funding in the form of grant.
27	11.07.2023	Machine Medicine	GBR	HealthTech	Brain Health Platform / On market	Developer of a healthcare platform designed to digitally detect the motor characteristics of Parkinson's disease.	A	< 1	4	The company joined Techstars on July 11, 2023 and received \$100,000 in funding.
28	10.07.2023	MedoSync	IRL	HealthTech	Digital Health / On market	Developer of medical billing software designed to deliver tailored healthcare services to the patient.	A	1	2	The company raised EUR 1.1 million of venture funding from Enterprise Ireland, JP Sisk, and Enrique Curran on July 10, 2023. The funds will be used to target healthcare providers, clinicians, and insurers in European markets.
29	07.07.2023	GlucoSet	NOR	MedTech	Diabetes Management / Undisclosed	Developer of a real-time intravascular blood glucose monitoring system designed to reduce harmful hypoglycemia.	A	6	7	The company raised EUR 6 million of Series A venture funding in a deal led by Swiss Diabetes Venture Fund on July 7, 2023. European Innovation Council Fund also participated in the round.
30	07.07.2023	CergenX	IRL	HealthTech	Health Monitoring Software / Undisclosed	Developer of brain screening technology designed to screen brain abnormalities in babies.	A	1	2	The company raised EUR 1.2 million of venture funding from Enterprise Ireland and other undisclosed investors on July 7, 2023. The funds will be used to support the development of the newborn brain screener, expanding its staff with roles in artificial intelligence, product management and software engineering and also accelerating the company's path to market.
31	07.07.2023	Milbotix	GBR	MedTech	Other / Developing	Developer of a smart sock designed to improve access to psychological or physical assistance for people with unmet needs related to a health condition.	A	< 1	< 1	The company raised GBP 224,989 of angel funding from undisclosed investors on July 7, 2023, putting the company's pre-money valuation at GBP 2.22 million.
32	07.07.2023	eholo	ESP	HealthTech	Care Management Platform / Undisclosed	Operator of a psychology management platform intended to optimize the time and focus on matters of psychologists and centers.	A	< 1	< 1	The company raised EUR 200,000 of venture funding in a deal led by Seedrocket on July 7, 2023. Other undisclosed investors also participated in the round. The funds will be used to expand its team and improve its advertising strategy.


Source: PitchBook as of 04-08-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	142	F
3	Amolyt Pharma	France	130	C
4	Ellipses Pharma	UK	126	A
5	Hemab Therapeutics	Denmark	125	B

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	European Innovation Council Fund	Germany	147	26
2	Revival Healthcare Capital	USA	142	2
3	Gilde Healthcare Partners	Denmark	108	8
4	Forbion	Denmark	102	8
5	Jeito	France	90	6

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
33	06.07.2023	TolerogenixX	DEU	Biotech / Pharma	Immunology / Phase II	Developer of a patented and clinically tested cell therapy technique created for individualized immunosuppression in transplant patients.	A	12	12	The company raised EUR 11.6 million of Series A venture funding from High-Tech Gründerfonds, Kalodion, and DB Speciality Invest on July 6, 2023. Nisus, Dr. Dr. Dorow, Dr. Dr. Fakler, and Biotech Mountains BV also participated in the round.
34	05.07.2023	Neko Health	SWE	MedTech	Medical Scanner / On market	Developer of a healthcare system designed to help people stay healthy through preventive measures and early detection.	A	60	66	The company raised EUR 60 million of Series A venture funding in a deal led by Lakestar on July 5, 2023. Atomico, General Catalyst and Prima Materia also participated in the round. The funds will be used to help accelerate company's strategic plans for expansion, continued investment in R&D, clinical studies, and recruitment of world-class talents.
35	05.07.2023	OncoDNA	BEL	HealthTech	Oncology / Pre-clinic	Operator of a theranostic and genomic company intended to provide precision medicine to treat cancer and genetic diseases.	C	7	50	The company raised EUR 6.66 million of Series C venture funding from SFPI, Wallonie Entrepreneurs and Banque CPH on July 5, 2023, putting the company's pre-money valuation at EUR 44.82 million. Ackermans & van Haaren, SambrInvest, Vesalius Biocapital Partners, Swisscanto Private Equity and other undisclosed investors also participated in the round. The funds will be used to achieve the company's goal of profitable and sustainable growth by providing personalized medicine.
36	04.07.2023	GenSensor	FRA	MedTech	Monitoring Device / Undisclosed	Developer a genomic-based monitoring system to optimize in-line bioproduction.	A	2	2	The company raised EUR 2 million of venture funding from GO Capital (France), Sodero Gestion and Epifrance on July 4, 2023. The funds will be used to finalize the industrial development of its robot, and to deploy the first applications in the field of gene therapy, vaccines and then antibody production.
37	04.07.2023	Paltech	FRA	MedTech	Diabetes Management / Undisclosed	Developer of a medical device intended to serve diabetes patients.	A	1	2	The company raised EUR 1.10 million of venture funding from undisclosed investors on July 4, 2023, putting the company's pre-money valuation, at EUR 12.02 million.
38	04.07.2023	Oncostellae	ESP	Biotech / Pharma	Oncology / Phase I	Developer of molecule drugs designed to focus on the treatment of autoimmune diseases.	A	< 1	8	The company raised EUR 500,000 of venture funding from Noso Capital on July 4, 2023.
39	04.07.2023	Aquarate	GBR	HealthTech	Monitoring Device / On market	Developer of a hydration tracking system designed to monitor hydration anywhere and anytime.	A	< 1	< 1	The company raised GBP 275,000 of angel funding from WCS Nominees, and other undisclosed investors on July 4, 2023, putting the company's pre-money valuation at GBP 5.00 million.
40	01.07.2023	Hylomorph	CHE	MedTech	Medical Implant / Developing	Developer of healthcare biomaterials intended to optimize the interface between implantable medical devices and biological tissues.	2	5	13	The company raised CHF 4.5 million of Series B2 venture funding from EFI Lake Geneva Ventures, Excellis and Club degli investitori on July 1, 2023, putting the company's pre-money valuation at CHF 18.01 million.


Source: PitchBook as of 04-08-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	142	F
3	Amolyt Pharma	France	130	C
4	Ellipses Pharma	UK	126	A
5	Hemab Therapeutics	Denmark	125	B

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	European Innovation Council Fund	Germany	147	26
2	Revival Healthcare Capital	US	142	2
3	Gilde Healthcare Partners	Denmark	108	8
4	Forbion	Denmark	102	8
5	Jeito	France	90	6

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
41	01.07.2023	ImageBiopsy Lab	AUT	HealthTech	Medical Imaging Technology / Developing	Developer of a medical imaging platform designed to help in the early detection of musculoskeletal diseases like arthritis, osteoarthritis, and osteoporosis.	2	3	9	The company raised EUR 3 million of Series A2 venture funding in the combination of convertible note and equity from IT-Farm on July 1, 2023.

Source: PitchBook as of 04-08-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Contact Details & Disclaimer



FCF Fox Corporate Finance GmbH

Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299
info@fcf.de ▪ www.fcf.de

Arno Fuchs

Chief Executive Officer

P: +49 (89) 206 0409-100
M: +49 (172) 863 6777
arno.fuchs@fcf.de

Mathias Klozenbuecher

Managing Director

P: +49 (89) 2060 409-123
M: +49 (174) 301 1846
mathias.klozenbuecher@fcf.de

Johannes Link

Associate

P: +49 (89) 206 0409-150
M: +49 (172) 839 5746
johannes.link@fcf.de

Marcel Louis Christou

Junior Analyst

P: +49 (89) 206 0409-127
marcellouis.christou@fcf.de

DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither FCF nor any of its officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This document contains certain forward-looking statements, including assumptions, opinions and views cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking statements are free from errors nor does FCF accept any responsibility for the future accuracy of the opinions expressed in this document or the actual occurrence of the forecasted developments.

© FCF Fox Corporate Finance GmbH 2023



THE FINANCING SPECIALIST